JP5976206B2 - 神経機能障害を検出するための造影剤 - Google Patents

神経機能障害を検出するための造影剤 Download PDF

Info

Publication number
JP5976206B2
JP5976206B2 JP2015513993A JP2015513993A JP5976206B2 JP 5976206 B2 JP5976206 B2 JP 5976206B2 JP 2015513993 A JP2015513993 A JP 2015513993A JP 2015513993 A JP2015513993 A JP 2015513993A JP 5976206 B2 JP5976206 B2 JP 5976206B2
Authority
JP
Japan
Prior art keywords
mmol
alkyl
reaction
added
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015513993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517572A5 (enExample
JP2015517572A (ja
Inventor
アンナ・カトリン・シャルデニングス
ハルトムート・ツェー・コルプ
ジョセフ・シー・ウォルシュ
ガン・チェン
ウメッシュ・ビー・ガンガーダルマト
ダナラクシュミ・カシ
リウ・チャンホイ
アンジャナ・シンハ
エリック・ワン
チュル・ユー
ウェイ・ツァン
カイ・チェン
ヴァニ・ピー・モチャルラ
ピーター・ジェイ・エイチ・スコット
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/477,095 external-priority patent/US8932557B2/en
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2015517572A publication Critical patent/JP2015517572A/ja
Publication of JP2015517572A5 publication Critical patent/JP2015517572A5/ja
Application granted granted Critical
Publication of JP5976206B2 publication Critical patent/JP5976206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
JP2015513993A 2012-05-22 2012-10-25 神経機能障害を検出するための造影剤 Active JP5976206B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/477,095 US8932557B2 (en) 2008-02-14 2012-05-22 Imaging agents for detecting neurological dysfunction
US13/477,095 2012-05-22
PCT/US2012/061912 WO2013176698A1 (en) 2012-05-22 2012-10-25 Carboline and carbazole based imaging agents for detecting neurological dysfunction

Publications (3)

Publication Number Publication Date
JP2015517572A JP2015517572A (ja) 2015-06-22
JP2015517572A5 JP2015517572A5 (enExample) 2015-10-15
JP5976206B2 true JP5976206B2 (ja) 2016-08-23

Family

ID=47146722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513993A Active JP5976206B2 (ja) 2012-05-22 2012-10-25 神経機能障害を検出するための造影剤

Country Status (9)

Country Link
EP (1) EP2852572B1 (enExample)
JP (1) JP5976206B2 (enExample)
KR (1) KR101609504B1 (enExample)
CN (2) CN107011342A (enExample)
AU (1) AU2012381042B2 (enExample)
CA (1) CA2873963C (enExample)
CO (1) CO7131359A2 (enExample)
ES (1) ES2792830T3 (enExample)
WO (1) WO2013176698A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
ES2788977T3 (es) 2014-04-22 2020-10-23 Univ Montreal Compuestos y uso de los mismos en la expansión de células madre hematopoyéticas y/o células progenitoras hematopoyéticas
WO2015173225A1 (en) 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Deuterated heterocyclic compounds and their use as imaging agents
EP3253762B1 (en) * 2015-02-02 2021-05-05 UCB Biopharma SRL 9h-pyrrolo-dipyridine derivatives
EP3266778A4 (en) * 2015-03-04 2018-11-14 Kyoto University RADIOACTIVE IODINE LABELED PYRIDO[1,2-a]BENZOIMIDAZOLE DERIVATIVE COMPOUND
TW201707726A (zh) * 2015-08-19 2017-03-01 國立大學法人京都大學 放射性鹵素標誌吡啶并［１，２－ａ］苯并咪唑衍生物化合物
BR112018006969B1 (pt) 2015-11-13 2022-04-26 Eli Lilly And Company Derivados de azetidina para formação de imagem de tau, seu intermediário, seu uso e seu processo de preparação, e composição
US10865207B2 (en) 2016-07-22 2020-12-15 Ac Immune S.A. Compounds for imaging Tau protein aggregates
KR102472003B1 (ko) 2016-07-22 2022-11-29 에이씨 이뮨 에스에이 타우 단백질 응집체를 이미징하기 위한 화합물
WO2018024642A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
WO2018024643A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
CA3042260C (en) * 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
CN109884194A (zh) * 2017-12-06 2019-06-14 新疆维吾尔药业有限责任公司 一种药用植物的分离方法及其产品和应用
US20210041447A1 (en) 2018-01-24 2021-02-11 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
CN108409634B (zh) * 2018-05-10 2021-04-27 曲阜师范大学 咔唑类荧光胺类化合物标记试剂、合成和应用
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
KR102215255B1 (ko) * 2019-06-12 2021-02-15 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 형광 탐침자로서 유효한 신규 화합물 및 이의 제조 방법
CN114867727B (zh) 2019-07-17 2025-02-21 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CN116003402B (zh) * 2021-11-02 2025-08-29 上海如絮生物科技有限公司 一种三环类化合物、其中间体、制备方法和应用
CN114539250B (zh) * 2022-03-04 2023-08-29 上海裕兰生物科技有限公司 一种阿尔兹海默症PET-tau示踪剂的制备方法
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024163546A1 (en) 2023-02-02 2024-08-08 Eli Lilly And Company Novel compounds for tau imaging
CN117050070B (zh) * 2023-07-05 2025-10-14 湘潭大学 一种荧光探针及其制备方法和在Aβ检测中的应用
WO2025155625A1 (en) 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005063A2 (en) * 2004-06-30 2006-01-12 Smithkline Beecham Corporation Methods and compositions
FR2885905A1 (fr) 2005-05-23 2006-11-24 Trophos Sa Nouveaux composes chimiques et leurs utilisations comme medicament
DE102006062203A1 (de) * 2006-12-22 2008-06-26 Curacyte Discovery Gmbh Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen
WO2008132454A1 (en) * 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
DK2247558T4 (da) * 2008-02-14 2024-07-29 Lilly Co Eli Nye billeddannelsesmidler til detektering af neurologisk dysfunktion
EP2323697A2 (en) * 2008-07-24 2011-05-25 Siemens Medical Solutions USA, Inc. Imaging agents useful for identifying ad pathology
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤
JP2012521988A (ja) * 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US10639608B2 (en) * 2010-04-08 2020-05-05 Siemens Medical Solutions Usa, Inc. System, device and method for preparing tracers and transferring materials during radiosynthesis
JP5585382B2 (ja) * 2010-10-22 2014-09-10 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、照明装置及び表示装置

Also Published As

Publication number Publication date
EP2852572A1 (en) 2015-04-01
KR101609504B1 (ko) 2016-04-05
AU2012381042B2 (en) 2015-10-01
EP2852572B1 (en) 2020-04-01
WO2013176698A1 (en) 2013-11-28
CO7131359A2 (es) 2014-12-01
AU2012381042A1 (en) 2014-11-20
KR20150002854A (ko) 2015-01-07
ES2792830T3 (es) 2020-11-12
JP2015517572A (ja) 2015-06-22
CN107011342A (zh) 2017-08-04
CA2873963A1 (en) 2013-11-28
CA2873963C (en) 2017-04-11
CN104781234A (zh) 2015-07-15

Similar Documents

Publication Publication Date Title
JP5976206B2 (ja) 神経機能障害を検出するための造影剤
US8932557B2 (en) Imaging agents for detecting neurological dysfunction
ES2907992T5 (en) Novel imaging agents for detecting neurological dysfunction
ES2578228T3 (es) Agentes de formación de imágenes para detectar trastornos neurológicos
EP2411057B1 (en) Imaging agents for detecting neurological disorders
CN102046638B (zh) 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物
HK1167393A1 (en) Tricyclic indole derivates as pbr ligands
HK1167393B (en) Tricyclic indole derivates as pbr ligands
HK1183021B (en) Imaging agents for detecting neurological disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160119

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160719

R150 Certificate of patent or registration of utility model

Ref document number: 5976206

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250